Free Trial

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 20 of 20

 
 

MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics logoMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
 
Trailing Twelve Months EPS: ($0.91)
2024 EPS Estimate: ($1.54)
2025 EPS Estimate: ($2.49)

Current Stock Price
$46.76
Consensus Rating
Moderate Buy
Ratings Breakdown
9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$80.45 (72.1% Upside)

More Investing Slideshows:

 

Market "Famine" Coming (Ad)

Market Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...

For a limited time, he's revealing his latest forecast here.